{"schema_version":"1.0","type":"article","title":"一季賣破 10 億，Alnylam 為何崩 28%？","url":"https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset.md","lang":"zh-Hant","date":"2026-08-05","publish_at":"2026-08-05T08:00:00+08:00","updated_at":"2026-08-05","category":"商業分析系列","topic":"商業分析系列","tags":["Alnylam","Amvuttra","RNAi","ATTR","小核酸藥物","生技股","合一","中天","智新生技","基米"],"summary":"Amvuttra 單季銷售突破 10 億美元，Alnylam 卻下修 TTR 指引並重挫 28%。真正被重估的不是 RNAi 技術，而是積壓需求退潮、收入集中與下一個商業支柱的時間差。","key_points":[],"facts":[],"sections":["01｜財報很好，壞消息藏在未來式","02｜2 億美元不大，86% 的集中度很大","03｜Wainua 三期失利，不能被寫成 RNAi 失效","04｜下一棒 nucresiran，要等的是臨床而不是口號","05｜台灣有臨床座標，沒有直接受惠股證據","06｜接下來，不要只盯下一季營收","結語｜技術沒有暴雷，估值先換檔","參考資料","免責聲明"],"references":[{"title":"[Alnylam","source":"2026 Q2 財務結果與全年指引更新]","date":"","url":"https://investors.alnylam.com/press-release?id=29986"},{"title":"[Alnylam","source":"2026 Q2 Form 10-Q]","date":"","url":"https://alnylampharmaceuticalsinc.gcs-web.com/static-files/df2ac46c-f252-4864-97e7-02db276e70db"},{"title":"[FDA","source":"Amvuttra（vutrisiran）處方標籤]","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215515s006lbl.pdf"},{"title":"[Ionis","source":"CARDIO-TTRansform topline 結果]","date":"","url":"https://ir.ionis.com/node/34896"},{"title":"[FDA","source":"Attruby 核准公告]","date":"","url":"https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-heart-disorder-caused-transthyretin-mediated-amyloidosis"},{"title":"[ClinicalTrials.gov","source":"TRITON-CM（NCT07052903）]","date":"","url":"https://clinicaltrials.gov/study/NCT07052903"},{"title":"[Nasdaq","source":"ALNY 歷史交易資料]","date":"","url":"https://www.nasdaq.com/market-activity/stocks/alny/historical"},{"title":"[合一","source":"SNS851 一期與共同開發公告]","date":"","url":"https://onenessbio.com/en/a-phase-1-clinical-trial-of-sns851-has-been-approved-by-australia-hrec-and-acknowledged-by-australia-tga/"},{"title":"[中天","source":"SNS851 共同開發公告]","date":"","url":"https://www.twmicrobio.com/tw/%E9%87%8D%E5%A4%A7%E8%A8%8A%E6%81%AF-17/"},{"title":"[基米","source":"短鏈核酸與 siRNA API 能力（2024 年報）]","date":"","url":"https://www.genomics.com.tw/upload/2025_09_11/2_202509111525141hcglwe9Y0.pdf"},{"title":"[櫃買中心","source":"智新生技（7832）公司概況與 RNAi／遞送研發]","date":"","url":"https://www.tpex.org.tw/storage/emerging_register/2025/04/1745477059_14400_CH_7832.pdf"},{"title":"[智新生技","source":"核心技術與 IG-001／IG-002]","date":"","url":"https://www.intelli-gene.com/tech"},{"title":"資料查證截止：2026-07-31（UTC+8）。","source":"","date":"","url":""}],"images":[{"alt":"Alnylam 與 Amvuttra 的營收成長與估值重估","url":"https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset/figure-01.png"},{"alt":"Alnylam 2026 年第二季產品收入集中度","url":"https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset/figure-02.png"},{"alt":"Amvuttra 上市後由積壓需求轉向常態需求的成長換檔","url":"https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset/figure-03.png"},{"alt":"Amvuttra、eplontersen 與 nucresiran 的臨床定位比較","url":"https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-05）。一季賣破 10 億，Alnylam 為何崩 28%？。https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-05-alnylam-amvuttra-ttr-growth-reset-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}